36周妊娠筛查后妊娠期高血压疾病的预测:血管生成标志物与竞争风险模型的比较
这项前瞻性观察研究在英格兰两家产科医院纳入34782例孕妇,于35+0至36+6周比较低PlGF、高sFlt-1/PlGF比值与竞争风险模型(单检、双检、三检)对子痫前期分娩的预测效能。在10%筛查阳性率下,三检模型对筛查后任意时间、2周内和1周内子痫前期分娩的检出率分别为68%、87%和91%,均高于低PlGF或sFlt-1/PlGF比值。
要点
- 35+0至36+6周筛查时,三检竞争风险模型对1周内子痫前期分娩的检出率达91%。
- 相同筛查阳性率10%下,三检模型对任意时间子痫前期分娩的检出率为68%。
- 三检模型对任意时间子痫前期的检出率相较低PlGF提高20.1%,相较sFlt-1/PlGF比值提高12.4%。
核心结论
- 在35+0至36+6周妊娠,竞争风险模型三检(母体因素+PlGF+sFlt-1+MAP)对筛查后1周内、2周内及任意时间发生子痫前期的筛查效能优于单用PlGF或sFlt-1/PlGF比值。
研究设计与样本
- 前瞻性观察研究,纳入2016年至2022年在英格兰两家产科医院于35+0至36+6周进行常规医院就诊的34782例孕妇,记录人口学特征和病史并检测血清PlGF、sFlt-1及平均动脉压,子痫前期按美国妇产科医师学会2019标准定义。
诊断标准与关键数值
- 低PlGF定义为低于第10百分位;高sFlt-1/PlGF比值定义为高于第90百分位;风险截断值对应10%筛查阳性率。
- 筛查后任意时间子痫前期分娩的检出率:低PlGF 47%、单检54%、高sFlt-1/PlGF比值55%、双检61%、三检68%。
- 筛查后2周内子痫前期分娩的检出率:低PlGF 67%、单检74%、高sFlt-1/PlGF比值74%、双检80%、三检87%。
- 筛查后1周内子痫前期分娩的检出率:低PlGF 77%、单检81%、高sFlt-1/PlGF比值85%、双检88%、三检91%。
- 三检模型对任意时间子痫前期的检出率相较低PlGF的差值(95%CI)为20.1%(16.7-23.0%),相较sFlt-1/PlGF比值为12.4%(9.7-15.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the performance at 35 + 0 to 36 + 6 weeks' gestation of screening for delivery with pre-eclampsia (PE) at various timepoints, using one of three approaches: placental growth factor (PlGF) concentration, soluble fms-like tyrosine kinase-1 (sFlt-1) to PlGF concentration ratio, or the competing-risks model, which combines maternal risk factors with biomarkers to estimate patient-specific risk.
METHODS: This was a prospective observational study of women attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation at one of two maternity hospitals in England between 2016 and 2022. During the visit, maternal demographic characteristics and medical history were recorded and serum PlGF, serum sFlt-1 and mean arterial pressure (MAP) were measured. Detection rates (DRs) were evaluated for delivery with PE (defined as per American College of Obstetricians and Gynecologists 2019 criteria) within 1 week, within 2 weeks or at any time after screening, using the following strategies: (i) low PlGF (< 10th percentile); (ii) high sFlt-1/PlGF ratio (> 90th percentile); or (iii) the competing-risks model, in which maternal factors were combined with multiples of the median values of PlGF ('single test'), PlGF and sFlt-1 ('double test') or PlGF, sFlt-1 and MAP ('triple test'). Risk cut-offs corresponded to a screen-positive rate of 10%. DRs were compared between tests.
RESULTS: Of 34 782 pregnancies, 831 (2.4%) developed PE. In screening for delivery with PE at any time from assessment, the DR at 10% screen-positive rate was 47% by low PlGF alone, 54% by the single test, 55% by high sFlt-1/PlGF ratio, 61% by the double test and 68% by the triple test. In screening for delivery with PE within 2 weeks from assessment, the respective values were 67%, 74%, 74%, 80% and 87%. In screening for delivery with PE within 1 week from assessment, the respective values were 77%, 81%, 85%, 88% and 91%. For prediction of PE at any time, the DR was significantly higher with the triple test compared to PlGF alone or the sFlt-1/PlGF ratio, with a DR difference (95% CI) of 20.1% (16.7-23.0%) and 12.4% (9.7-15.3%), respectively. Similar results were seen for prediction of PE within 2 weeks (20.6% (14.9-26.8%) and 12.9% (7.7-17.5%), respectively) and prediction of PE within 1 week (13.5% (5.4-21.6%) and 5.4% (0.0-10.8%), respectively). The double test was superior to the sFlt-1/PlGF ratio and the single test was superior to PlGF alone in the prediction of PE within 2 weeks and at any time from assessment, but not within 1 week of assessment.
CONCLUSION: At 35 + 0 to 36 + 6 weeks' gestation, the performance of screening for PE by the competing-risks model triple test is superior to that of PlGF alone or the sFlt-1/PlGF ratio for the development of disease within 1 week, within 2 weeks and at any time from screening. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Schiattarella A, Magee LA, Wright A, et al. Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing-risks model. Ultrasound Obstet Gynecol. 2023. PMID: 37329494. doi:10.1002/uog.26291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。